Navigation Links
Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation
Date:9/19/2008

From Neurons to Beyond; Advancing the Frontiers of Life Science Research Toward Realizing Healthcare Solutions in Areas of Clinical Need Such as Parkinson's, Alzheimer's, and Autism

BOSTON, Sept. 19 /PRNewswire/ -- Neurosilicon (http://www.neurosilicon.com) has announced the availability of their innovative Photoconductive Stimulation Device (PSD). The PSD allows researchers to induce rapid, non-invasive activation of excitable cells, such as neurons. This novel research innovation will enable researchers to significantly expand the depth, breadth, and complexity of experimental research approaches aimed at understanding and addressing areas of unmet healthcare need such as in Parkinson's disease, Alzheimer's, and Autism. The PSD makes use of a property called the Photoconductive Stimulation Effect (PSE). This novel device is based on the PSE principle that states when visible light strikes silicon in combination with a specific current, a local field potential (LFP) is generated. This LFP can be harnessed to initiate depolarization in excitable cells without causing any damage to the cell. Further, the PSD induced depolarization can be applied at user-definable frequency, intensity, and duration, further extending experimental variation, design, and control. Taken together, the PSD will enable laboratory researchers and industry technicians to depolarize excitable cells in a highly targeted and readily reproducible manner significantly extending the breadth and depth of experimental protocols, as well as enabling high throughput testing, sample screening, and drug discovery.

This technology provides researchers with the means to dynamically study excitation dependent cellular responses without the requirement for a direct physical link to the cell (such as with electrodes used for patch clamping or transistor contact necessary for use with micro electrode arrays). The non-invasive, optical targeting used by the PSD allows for an extended observation period, dependent only upon the environmental support available for the cells. Further, non-invasive electrical stimulation can be done without causing damage to the cells while optical targeting enables highly controlled depolarization of only target cells. The PSD can also be used in place of pharmacological agonist stimulation, which does not allow for specific cell targeting and/or rapid repetitive depolarization, where such experimental capabilities would be desirable.

The PSD system controller is a fully contained, easy to use electronics base that readily fits into any bench-top environment. Cells for experimentation are grown on the silicon PSD substrates that fit in industry standard 24 well plates for cell culture and storage, and are then mounted onto the reusable PSD experimental chamber for live cell observation using any standard up-right microscope. Current promotion bundles including the PSD controller, experimental chambers, and cell culture substrates begin at $3,550.00.

Advancing the frontiers of excitable cell research, such as in neurons and muscle cells will serve to further our understanding of the mechanisms underlying cellular structure/function relationships. Additionally, it will enable scientists to better elucidate how these mechanisms go awry during disease states and potentially how to better address (and/or prevent) the disease state (and/or injury) following onset. Further, the diagnostic testing and drug discovery potential of the PSD will provide insights into the identification and development of new therapeutics.

About Neurosilicon

Neurosilicon develops novel brain-computing interfaces to expand the scientific understanding of the human brain and to revolutionize and improve the effectiveness of drug discovery. The company's flagship product, the Photoconductive Stimulation Device (PSD) stimulates excitable cells in a precise and controllable fashion. Neurosilicon is comprised of a multidisciplinary team of neuroscientists and engineers. Together this team has spent three years developing, testing, and optimizing their novel photoconductive stimulation technology, significantly advancing the boundaries of life science research.

For more information on the Photoconductive Stimulation Device (PSD), or to order, please visit http://www.neurosilicon.com.


'/>"/>
SOURCE Neurosilicon
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
2. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
3. Novel Compound Shows Promise for Treatment of Alcoholism
4. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
5. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
6. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
7. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
8. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
9. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
10. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
11. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Business Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants ... Canada , Japan , ... , and Rest of World. Annual estimates and ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The IPF pipeline is very strong with a total of ... Co., Inc., Biogen and Sanofi are involved in the development of the ... one is in Phase III stage, 15 are in Phase II stage, ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... of inspiring stories about real people of God in congregations across the United ... Miller, a Presbyterian minister ordained in 1964 who has served congregations in seven ...
(Date:3/23/2017)... Greensboro, NC & Seattle, WA (PRWEB) , ... March 23, 2017 ... ... international public health emergency and now estimates that there could be four million Zika-related ... fastest growing epidemics to date with numbers of US cases reported per year skyrocketing ...
(Date:3/23/2017)... Houston, Texas (PRWEB) , ... March 23, 2017 , ... ... their 3rd location in the greater Houston Area. The new location is located at ... St. Luke’s Hospital in Springwoods Village. This newest location will provide patients living in ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
(Date:3/23/2017)... ... 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the way ... impact on businesses and individual consumers alike. Laboratories can maximize their profit margin ... anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects ...
Breaking Medicine News(10 mins):